×

Leadership Corporate Leaders

  • yahoo_HQ4.jpg

    The company is recounting the shareholder vote for its board of directors after discovering that a tabulating firm failed to register the opposition of a major investor.

  • The board of directors at General Motors remains supportive of Chief Executive Rick Wagoner, despite the company's recent, unexpected $15.5 billion loss, the Wall Street Journal reported Tuesday.

  • Bob Lutz

    GM Vice Chairman Bob Lutz invited me to watch him test the E-Flex system behind the new Chevy Volt. Given the enthusiasm surrounding the Volt, I jumped at the opportunity. Would E-Flex deliver on the promise that's been built up surrounding GM's electric car? The answer: Yes.

  • freddie_mac_logo.jpg

    The chief executive of the mortgage giant Freddie Mac rejected internal warnings that could have protected the company from some of the financial crises now engulfing it, according to more than two dozen current and former high-ranking executives and others, the New York Times reported.

  • Today on CNBC, Merrill Lynch CEO John Thain gave an exclusive interview, and the chairman of Rosen Real Estate Securities claimed that economic recession has only just begun. What follows are today's top videos:

  • imclone_logo_new.jpg

    Just before the opening bell this morning ImClone Systems put out a clearly Carl Icahn-inspired press release regarding last week's $60-a-share buyout offer from Bristol-Myers Squibb.

  • After almost 10 years of covering General Motors, including the last year going behind the scenes for our upcoming documentary "Saving GM", I often hear the same question time and again. Where is chairman and CEO Rick Wagoner taking this company?

  • James Cayne

    Former Bear Stearns Chief Executive James Cayne came close to dying last September from sepsis triggered by a severe prostate infection, Fortune Magazine reports Monday on its website.

  • A massive switch to natural gas would free the U.S. from its dependence on foreign oil.

  • What a crazy week, right? Monday, Amgen had a huge upside revenue and earnings surprise. Tuesday, the Food and Drug Administration issued its new restrictions on the use of Amgen's anemia drugs in certain cancer patients. Later that same day, Elan and Wyeth released the big Alzheimer's drug test results.

  • GM_logo_down.jpg

    We knew GM's second quarter earnings would be ugly, but I'm not sure many people expected this kind of number. Certainly Wall Street didn't since the estimate was for GM to lose $1.489 Billion. Turns out Gm's loss was 4 times worse: $6.3 Billion.

  • It's hard to worry about a company that holds $10.8 billion in its backlog.

  • I was told to leave the building immediately otherwise security would be called and it "would get ugly." That's a quote from an AA staffer. It didn't get ugly. We quickly packed up all our stuff and moved outside.

  • Carl Icahn

    Investor Carl Icahn, who ran a heated proxy battle to unseat the Yahoo board and oust its chief executive, said he will not be attending the Internet company's annual meeting Friday.

  • New BT CEO Ian Livingston is fighting market prejudice. The telecom sector remains unloved. Most of the sector analysts are struggling to be positive about the pricing environment, and the pinch on consumer spending is only set to worsen.

  • General Motors logo

    Friday, Wall Street analysts are expecting GM to lose $1.489 billion. If they are right, the loss will be just short of the $1.631 billion GM lost (excluding charges) in that woeful third quarter of 2007.

  • And Oracle. As the CEO explains, none of the company's peers can compete.

  • Former and current CEOs across various industries discussed the economy, energy prices, the state of the airline industry and more on CNBC this morning.

  • Nearly a year and a half after it was announced, the merger deal between Sirius Satellite Radio and XM Satellite Radio is an accomplished fact, and the chief executive of the combined company sees strong signals for the future.

  • When covering this beat you often have to become as fluent as possible in different disease jargon. But nothing could have prepared me for the alphabet soup served up in this highly anticipated release.